NASDAQ: CYTOAltamira Therapeutics Ltd Stock
$1.41-0.09 (-6%)
Updated Apr 19, 2024
CYTO Price
$1.41
Fair Value Price
N/A
Market Cap
$2.09M
52 Week Low
$1.41
52 Week High
$28.40
P/E
-0.16x
P/B
0.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$14M
Beta
0.88
Next Earnings
May 16, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CYTO Overview
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYTO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CYTO is good value based on its book value relative to its share price (0.29x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
CYTO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CYTO due diligence checks available for Premium users.
Be the first to know about important CYTO news, forecast changes, insider trades & much more!
CYTO News
Valuation
CYTO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
15.81x
Market
40.51x
CYTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.29x
Industry
5.74x
CYTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CYTO's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CYTO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.2M
Liabilities
$1.5M
Debt to equity
0.19
CYTO's short-term assets ($1.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYTO's short-term assets ($1.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYTO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CYTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYTO vs Biotech Stocks
Altamira Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.